Nature study shows: BGM0504, developed with the help of AI and molecular dynamics, has outstanding potency

Shanghai (ots/PRNewswire) – The molecular design strategy and experimental results of Bright Gene’s dual GLP-1/GIP receptor agonist, BGM0504, were published online on July 19, 2024 in Scientific Reports, a journal published by Nature Research. Bright Gene (stock code: 688166.SH) is an innovative, internationally emerging pharmaceutical company focused on developing best-in-class medicines to improve the health of patients worldwide.

The article entitled “Molecular Dynamics Guided Optimization of BGM0504 Enhances Dual Target Agonism for Combating Diabetes and Obesity” presents the results of the development of BGM0504 .

BGM0504, an AI-developed dual GIP and GLP-1 receptor agonist, shows both in In-vitro as well as in In-vivo-Experiments have superior effectiveness. Using AI-driven computer simulations, Bright Gene has discovered that optimal interaction between the glutamate residues on both GLP-1R and GIPR and the K20 residue of a peptide agonist provides superior activity. This interaction is an important finding that is not evident in cryo-EM studies. BGM0504 was designed to retain the free amino group of the K20 residue by moving the acylation point to position 40 of BGM0504. This design resulted in a threefold increase in agonist effects on GLP-1R and GIPR, with superior therapeutic outcomes in diabetic and obese mouse models.

Information about Bright Gene and BGM0504

Bright Gene (stock code: 688166.SH) is an innovative pharmaceutical company focused on developing first-in-class medicines. The company integrates active ingredients and formulations, combining generic and innovative medicines to meet global clinical needs. BGM0504 is a dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes, obesity and NASH and is currently in late-stage Phase II clinical trials.

Reference

Yuan, J., Liu, W., Jiang, X. et al. Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity. Science Report 14, 16680 (2024). https://doi.org/10.1038/s41598-024-66998-8

Photo – https://mma.prnewswire.com/media/2465893/image_5031720_25221542.jpg

View original content:https://www.prnewswire.com/news-releases/nature-studie-zeigt-das-mit-hilfe-von-ki-und-molekulardynamik-entwickelte-bgm0504-besitzt-eine-uberragende-potenz-302202798.html